BioArctic is pleased to announce that the company has been recognized with a highly commended accolade in the category EU Capital Market Transaction of the Year at the 2018 Lifestars Life Science Awards in London. The award recognizes a European company that has successfully completed a significant or transformational IPO in the period September 1, 2017 to September 1, 2018.
The judges paid particular attention to amount of funds raised, process/speed /allocation fulfilment of securing significant new funds, level/reputation of new investor(s) attracted, post-finance allocation/use of proceeds as well as level of value creating/value realization from raise.
“BioArctic had a successful IPO as well as a great first year as a listed company. I am very pleased that BioArctic was recognized with a highly commended accolade in the category EU Capital Market Transaction of the Year at the Lifestars Life Science Awards in London recently,” said Gunilla Osswald, CEO of BioArctic.
About Lifestars Life Science Awards 2018
Lifestars Life Science Awards is a celebration of the success stories, innovations, transformational deals and the people, teams and organizations that play such a critical role in the advancement of the industry over the last 12 months across Europe and the US. The international awards brought together over 300 global life science leaders, investors and deal makers and key stakeholders from the wider life science eco-system to recognize the achievements of the industry. Lifestars Life Science Awards was held in November during the Jefferies Annual Healthcare Conference week in London, Europe’s largest healthcare investment banking conference.